These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273 [TBL] [Abstract][Full Text] [Related]
8. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Syrigos KN; Epenetos AA Anticancer Res; 1999; 19(1A):605-13. PubMed ID: 10226606 [TBL] [Abstract][Full Text] [Related]
9. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Baxter LT; Jain RK Br J Cancer; 1996 Feb; 73(4):447-56. PubMed ID: 8595158 [TBL] [Abstract][Full Text] [Related]
11. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872 [TBL] [Abstract][Full Text] [Related]
12. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501 [TBL] [Abstract][Full Text] [Related]
14. Beta-glucuronidase-mediated drug release. de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215 [TBL] [Abstract][Full Text] [Related]
15. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598 [TBL] [Abstract][Full Text] [Related]
17. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study. Springer CJ; Poon GK; Sharma SK; Bagshawe KD Cell Biophys; 1994; 24-25():193-207. PubMed ID: 7736524 [TBL] [Abstract][Full Text] [Related]